Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ER-004

            Therapeutic Area: Genetic Disease Product Name: EDI200

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pierre Fabre

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 14, 2020

            Details:

            The Pierre Fabre group will be granted exclusive worldwide rights for the development, manufacturing and commercialization of ER-004. EspeRare and the Pierre Fabre Group will pool their respective expertise together in order to co-develop ER-004.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PHA-022121

            Therapeutic Area: Genetic Disease Product Name: PHVS416

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Viking Global Investors

            Deal Size: $80.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing November 18, 2020

            Details:

            The proceeds from the Series C financing will fund the clinical advancement of Pharvaris’ pipeline of novel oral bradykinin-B2-receptor antagonists for the treatment of HAE, including both on-demand treatment and prophylactic prevention.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PHA121

            Therapeutic Area: Genetic Disease Product Name: PHVS416

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            The PK/PD profile suggests that rapid onset of action and prolonged efficacy with a single dose of PHA121 in the treatment of acute HAE attacks. Pharvaris is preparing to start an on-demand study of PHVS416, a soft capsule formulation of PHA121, for HAE attacks in 2021.